%0 Journal Article
%T Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice.
%A Ståhle M
%A Silvola JMU
%A Hellberg S
%A de Vries M
%A Quax PHA
%A Kroon J
%A Rinne P
%A de Jong A
%A Liljenbäck H
%A Savisto N
%A Wickman A
%A Stroes ESG
%A Ylä-Herttuala S
%A Saukko P
%A Abrahamsson T
%A Pettersson K
%A Knuuti J
%A Roivainen A
%A Saraste A
%J JACC Basic Transl Sci
%V 5
%N 4
%D Apr 2020
%M 32368695
%F 9.531
%R 10.1016/j.jacbts.2020.01.008
%X This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.